[First NOAk specific antidote as additional safety factor in therapy].
出版信息
MMW Fortschr Med. 2016 Feb 4;158(2):66-7.
PMID:27017635
Abstract
摘要
相似文献
1
[First NOAk specific antidote as additional safety factor in therapy].[首个诺阿克特异性解毒剂作为治疗中的额外安全因素]
MMW Fortschr Med. 2016 Feb 4;158(2):66-7.
2
[First NOAK with specific antidote].
MMW Fortschr Med. 2015 Dec 14;157(21-22):84. doi: 10.1007/s15006-015-7626-6.
3
[First NOAK antidote soon to be approved].首款诺阿克解毒剂即将获批。
MMW Fortschr Med. 2015 Aug 20;157(14):34. doi: 10.1007/s15006-015-3409-3.
4
[Anticoagulant activity is rapidly reversed].抗凝活性迅速逆转。
MMW Fortschr Med. 2016 Feb 4;158(2):67.
5
[Dabigatran specific antidote: new safety level in oral anticoagulation].
MMW Fortschr Med. 2015 Nov 5;157(19):78-9.
6
[First new oral anticoagulant with specific antidote].[首款具有特异性解毒剂的新型口服抗凝药]
MMW Fortschr Med. 2016 Mar 17;158(5):73. doi: 10.1007/s15006-016-7952-3.
7
Reversal of dabigatran-associated bleeding using idarucizumab: review of the current evidence.达比加群相关出血的逆转药物idarucizumab：当前证据回顾。
J Thromb Thrombolysis. 2017 Nov;44(4):527-535. doi: 10.1007/s11239-017-1555-4.
8
Pharmacologic Reversal of Direct Oral Anticoagulants.直接口服抗凝剂的药理学逆转
Crit Care Nurs Q. 2018 Apr/Jun;41(2):121-128. doi: 10.1097/CNQ.0000000000000193.
9
[Treatment with inhibitors of new oral direct anticoagulants in patients with severe bleedings or urgent surgical procedures. The new dabigatran antidote: the place of idarucizumab in clinical practice].[新型口服直接抗凝剂抑制剂在严重出血或紧急外科手术患者中的治疗。新型达比加群解毒剂：依达赛珠单抗在临床实践中的地位]
Orv Hetil. 2016 Mar 20;157(12):443-50. doi: 10.1556/650.2016.30391.
10
[NOAC: Real-life data and the role of antidotes for the treatment of bleeding].[新型口服抗凝药：治疗出血的真实数据及解毒剂的作用]
Med Klin Intensivmed Notfmed. 2017 Mar;112(2):99-104. doi: 10.1007/s00063-016-0258-5. Epub 2017 Jan 31.
Zotero 插件